Summary
In a phase II study, 77 patients with metastatic breast cancer were treated with pirarubicin, 70 mg/m2 iv every 3 weeks. Most of them had received prior hormonal (n = 39) and/or chemotherapeutic drug treatment for advanced disease, including anthracycline-containing regimens in 17. After a median of 5.5 treatment cycles (range 1–14), objective tumor response was seen in 22/71 (31%) evaluable patients (4CR, 18 PR). Stable disease occurred in 34 (48%) patients, whereas the tumor progressed in 15 (21%). Significant hematologic toxicity (WHO grade III–IV) requiring interval and/or dose adjustments was observed in 41 (58%) patients. Other treatment-related side effects were generally mild, and included alopecia in 52 (73%), nausea and/or emesis in 50 (70%), and stomatitis and diarrhea in 3 patients each. There was no treatment-related death, nor was there any evidence of cardiac toxicity thus far. In summary, the early results of this trial suggest that pirarubicin is an active and rather well tolerated drug in pretreated patients with advanced breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Umezawa H, Takahashi Y, Kinoshita M, Naganawa H, Masuda T, Ishizuka M, Tatsuta K, Takeuchi T: Tetrahydropyranil derivates of daunomycin and adriamycin. J Antibiot 32: 1082–1084, 1979
Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y: 4′-o-tetrahydropyraniladriamycin as a potent new antitumor agent. Cancer Res 42: 1462–1467, 1982
Dantchev D, Paintrand M, Hayat M, Bourut C, Mathe G: Low heart and skin toxicity of tetrahydropyranil derivative of adriamycin (THP-ADM) as observed by electron and light microscopy. J Antibiot 32: 1085–1086, 1979
Majiama H: Preliminary phase II clinical study of 4′-o-te-trahydropyranil doxorubicin (THP-ADM). Gan To Kagaku Ryoho 10: 805–810, 1983
Nakada H, Ogawa M, Miyamato H, Inagaki J, Horikoshi N, Inoue K, Ikeda K, Usui N, Adachi K, Okada Y: Phase II study of 4′-o-tetrahydropyranyladriamycin (THP-ADM). Gan To Kagaky Ryoho 11: 138–142, 1984
Wakui A, Yokoyama M, Konno K, Nakai Y, Sakano T, Koyama Y, Imamura Y, Nakajima O, Niijiima T, Akaza H, Kimura I, Ohnoshi T, Hiraki S, Kato T, Nishimura H, Umezu J, Saito T: Phase I trial of 4′-o-tetrahydropyranil doxorubicin (THP), a multi-institutional cooperative study. Gan To Kagaku Ryoho 12: 118–124, 1985
Ogawa M, Miyamoto H, Inagaki J, Horikoshi N, Ezaki K, Inoue K, Ikeda K, Usui N, Nakada H: Phase I clinic trial of a new anthracycline, 4′-o-tetrahydropyranil-adriamycin. Gan To Kagaku Ryoho 10: 129–133, 1983
Majima H: Exploratory clinical study of 4′-otetrahydropyranil doxorubicine (THP-ADM), Phase I. Gan To Kagaku Ryoho 10: 134–140, 1983
Miller AA, Scheulen ME, Kleeberg UR, Seeber S, Schmidt CG: Phase I study of pirarubicin. J Cancer Res Clin Oncol 114: 91–94, 1988
WHO Handbook for Reporting Results of Cancer Treatment, WHO offset publication No 48, Geneva, 1979
Kaplan EL, Meier B: Non-parametric estimation from incomplete observations, J Am Stat Assoc 53: 457–481, 1957
Hoogstraten B, Fabian C: A reappraisal of single drugs in advanced breast cancer. Cancer Clin Trials 2: 101–109, 1979
Neidhard JA, Gochnour D, Roach RW, Steinberg JA, Young D: Mitoxantrone versus doxorubicin in advanced breast cancer: a randomised cross-overtrial. Cancer Treat Rev 10 (Suppl. B): 41–46, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Scheithauer, W., Samonigg, H., Depisch, D. et al. Pirarubicin (4′-o-tetrahydropyranil-adriamycin) for treatment of advanced breast cancer. Invest New Drugs 8, 207–210 (1990). https://doi.org/10.1007/BF00177262
Issue Date:
DOI: https://doi.org/10.1007/BF00177262